Skip to main content
Aquestive Therapeutics, Inc. logo

Aquestive Therapeutics, Inc. — Investor Relations & Filings

Ticker · AQST ISIN · US03843E1047 US Manufacturing
Open in API
Filings indexed 607 across all filing types
Latest filing 2019-05-08 Board/Management Inform…
Country US United States of America
Listing US AQST

About Aquestive Therapeutics, Inc.

https://aquestive.com/

Aquestive Therapeutics is a pharmaceutical company that develops and commercializes medicines using its proprietary PharmFilm® technology. This oral film drug delivery system provides a non-invasive and convenient alternative to conventional therapies, such as injections, by enabling the oral administration of complex molecules. The company's development pipeline is focused on addressing unmet medical needs in central nervous system (CNS) disorders and severe allergic reactions. Key product candidates include Anaphylm™, an epinephrine sublingual film for the emergency treatment of anaphylaxis, and Libervant®, a diazepam buccal film for the management of seizure clusters.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 90% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text includes an Item 2.02 section titled 'Results of Operations and Financial Condition' referencing a press release with financial results for the quarter ended March 31, 2019. It also includes Item 5.02 about the appointment and compensation of a senior executive. The document is not a full quarterly or annual report but a current report announcing financial results and management changes. The presence of management appointment details aligns with Board/Management Information filings. The financial results announcement is typical for an 8-K but does not contain comprehensive financial statements or detailed analysis, so it is not an Interim/Quarterly Report (IR) or Annual Report (10-K). Therefore, the best classification is Board/Management Information (MANG) due to the executive appointment and compensation details, with some financial results announcement included. Confidence is high given the clear presence of management change information and the nature of the 8-K filing.
2019-05-08 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is identified as a Schedule 14A filing, which is a definitive proxy statement or definitive additional materials related to proxy solicitation under the Securities Exchange Act of 1934. The text explicitly states it is a 'Definitive Additional Materials' filing related to a proxy statement. Proxy statements and related materials are classified under 'Proxy Solicitation & Information Statement' (PSI). The document length is short (2113 characters) and contains no financial data or report content, confirming it is not an annual report or other financial report but rather proxy solicitation materials.
2019-04-26 English
DEF 14A
Proxy Solicitation & Information Statement
2019-04-26 English
PRIMARY DOCUMENT
Director's Dealing
2019-04-01 English
PRIMARY DOCUMENT
Director's Dealing
2019-04-01 English
10-K
Annual Report FY 2018
2019-03-14 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.